NCT03742388Unknown不适用
A Genomic Analysis on the Evolution of Epithelia Ovarian Tumors
Lei Li1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2018年11月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Frequencies of somatic driving mutations
研究概览
简要总结
Epithelial ovarian carcinomatous and borderline components sometimes appeared in one patient. This study aims to analyze the genomic patterns of the carcinomatous and borderline components in the ovarian epithelial tissues. These tissues will be collected from paraffin section by microdissection to distinguish normal, carcinomatous and borderline tissues.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Confirmed primary epithelial ovarian borderline tumor with cancer
- •Signed an approved informed consents
- •Feasible for sampling
排除标准
- •Not meeting all of the inclusion criteria
结局指标
主要结局
Frequencies of somatic driving mutations
时间窗: Two years
The differences of frequencies of somatic driving mutations will be compared between normal, carcinomatous and borderline tissues.
次要结局
- Progression-free survival(Five years)
研究者
Lei Li
Professor
Peking Union Medical College Hospital
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
3 期
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian CancerOvarian NeoplasmsOvarian, Fallopian Tube and Primary Peritoneal CarcinomaNCT03602859Tesaro, Inc.1,400
招募中
不适用
Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA).Ovarian CancerNCT06229522Centro di Riferimento Oncologico - Aviano150
Unknown
不适用
A Multi-omics Study of Epithelial Ovarian CancerTumor InvasivenessWhole Exome SequencingTranscriptomicsMetabolomicsTumorigenesisEpithelial Ovarian CancerNCT03742856Lei Li80
已完成
不适用
Ovarian Tumor Biopsies to Study Response to TreatmentsEpithelial Ovarian CancerNCT02952521University Health Network, Toronto5
终止
1 期
Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian CancerOvarian NeoplasmsNCT00137865EGEN, Inc.18